- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01347567
Heart Failure (HF) Outpatient Monitoring Evaluation (HOME) Study (HOME)
HF Outpatient Monitoring Evaluation (HOME) Study
Study Overview
Status
Intervention / Treatment
Detailed Description
Systolic dysfunction heart failure subjects with low ejection fraction and elevated BNP levels admitted to hospital or treated as outpatient for decompensated Heart Failure (HF) are at hight risk for recurrent decompensation and readmission. The objective of this study is to investigate if these patients may benefit from enhanced home monitoring of their HF status.
In the 3 study arms (BNP, Health Management and control groups) home fingerstick BNP levels will be obtained so that frequent data points are available for analysis of trends and variability. These results will remain blinded to the subjects in all study arms and their care providers in the health management and control arms, the investigator and staff will have access to the BNP results only for subjects in the BNP arm and will use this information to aid in therapy decisions.
Subjects are monitored for 180 days as this time period is likely sufficient to differentiate normal biological variation in BNP changes due to impending decompensation.
Patients will be assessed at Day 30,90 and 180 after randomization HF status, patient clinical outcome and treatment adjustments are recorded.
Follow-up telephone calls to subjects at 3 and 6 months after completion of home testing will be conducted in order to determine the possible long-term benefit of home health management with daily BNP testing.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Queensland
-
Herston, Queensland, Australia, 4029
- Royal Brisbane and Women's Hospital
-
-
-
-
-
Dublin, Ireland
- St Vincent's Private Hospitale LTd
-
-
-
-
-
Gronongen, Netherlands, 9713
- University Medical Center Groningen
-
-
-
-
-
Auckland, New Zealand, 1142
- University of Auckland
-
Christchurch, New Zealand
- Department of Medicine, University of Otago
-
-
-
-
-
Linkoping, Sweden, 58185
- Linkoping University Hospital
-
-
-
-
-
London, United Kingdom
- Royal Brompton Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Adults (18 years of age and <75 years of age); AND
- Admitted to the hospital or treated in an outpatient clinic with a diagnosis of decompensated HF for which treatment will be administered;
i. BNP > 300 pg/mL (or NT-pro-BNP > 1500 pg/mL) during hospital admission or clinic visit.
OR c. Seen in an outpatient setting (i.e. heart failure clinic, general practice or cardiology office, urgent care unit) with a documented history of HF and with signs of worsening HF condition or decompensation, where worsening HF condition is defined as one or more of the following;
i. Increase in NYHA class with worsening symptoms (i.e. dyspnea, fatigue) at same level of activity ii. Symptoms requiring change in dosage of one or more of the following medications:
- diuretic
- beta blocker
ACE inhibitor iii. Physical evaluation consistent with worsening HF signs (i.e. elevated JVP, ankle edema, dyspnea, abdominal distension, >4 lb or >1.8 kg weight increase in past week) iv. HF admission in last 30 days with a documented BNP > 300 pg/mL (or NT-pro-BNP > 1500 pg/mL) during or since admission AND d. Presence of left ventricular systolic dysfunction (ejection fraction <40%); e. Successfully trained and deemed proficient on how to perform a fingerstick and to use the Test System. Each subject will undergo two proficiency assessments.
i. The first assessment will be performed at the time in which the subject is found to meet the inclusion criteria, and deemed willing, able and reliable to complete the study tasks, and following initial training on the use of the test system. Successful completion of this first proficiency assessment will result in the enrolment of the subject into the study.
The second assessment will be performed following one week (7 days ± 2 days) of home testing to demonstrate retention of the training. Successful completion of this second proficiency assessment will result in randomization of the subject into one of the three study arms of the study. Failure to demonstrate proficiency at this second assessment will result in the withdrawal of the subject from the study.
Exclusion criteria:
- Unwilling or unable to provide written informed consent;
Acute coronary syndrome (ACS) that is a primary diagnosis; or secondary diagnosis that is concomitant with the primary diagnosis of decompensated HF and for which treatment will be provided.
Note: A history of ACS is not cause for exclusion if it is not concomitant with the present decompensated HF for which admission is being made. Small elevations in cardiac troponin that are considered by the treating physician to be associated with myocardial injury due to the acute decompensated HF and not due to a concomitant ACS or myocardial infarction are not a basis for exclusion.
- Previous cardiac transplantation - or cardiac transplantation anticipated within 3 months;
- Current or planned use of a left ventricular assist device (LVAD), use of outpatient intravenous inotropic HF therapy, major surgical procedure or percutaneous coronary intervention within 3 months;
- Life expectancy less than 6 months due to causes other than HF or cardiovascular disease (e.g., cancer);
- End stage renal disease (dialysis dependency);
- Receiving any investigational medication;
- Hematocrit outside the 25 to 50% range of the HeartCheck system;
- Prisoner or other institutionalized or vulnerable individual;
- Dementia, tremors or other impediments to performing daily home BNP testing via fingerstick (unless BNP testing will be conducted by qualified caregiver);
- Deemed by the investigator not to be likely to comply with study-mandated procedures or instructions;
- Residence in regions where either transmission of test system data or home visits are not possible.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: BNP + Health Management
Subjects will provide information from home regarding weight,signs and symptoms, and will perform BNP self testing.
This information including BNP results will be used by the investigator as an aid to treatment decisions.
BNP results are blinded to subjects.
|
Therapeutic interventions with heart failure medications per decision of treating physician for subjects in all study arms but using the different information available in each study arm.
|
Active Comparator: Health Management
Subjects will provide information from home regarding weight, signs and symptoms, and will perform BNP self testing .
BNP results will be blinded to the investigator and subject; weight, signs and symptoms will be used by the investigator as an aid to treatment decisions
|
Therapeutic interventions with heart failure medications per decision of treating physician for subjects in all study arms but using the different information available in each study arm.
|
Placebo Comparator: Control
Subject will provide information from home regarding weight, signs and symptoms and will perform BNP self testing.
All these data will be blinded to the investigator.
BNP results will be blinded to the subject.
|
Therapeutic interventions with heart failure medications per decision of treating physician for subjects in all study arms but using the different information available in each study arm.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Average number of "hard' events per subject
Time Frame: Over 180 days
|
With hard events defined as:
|
Over 180 days
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Kenneth McDonald, Professor, St Vincent's Private Hospitale Ltd, Dublin, Ireland
- Principal Investigator: Henry Dargie, Professor, Western Infirmary, Glasgow, UK
- Principal Investigator: Theresa McDonagh, Professor, Royal Brompton, London, UK
- Principal Investigator: John Atherton, Professor, Royal Brisbane and Women's Hospital, Herston, Australia
- Principal Investigator: Henry Krum, Professor, Monash University
- Principal Investigator: Richard Thoughton, Professor, University of Otago, Christchurch, New Zealand
- Principal Investigator: Rob Doughty, Professor, University of Auckland, Victoria, New Zealand
- Principal Investigator: Faiez Zannad, Professor, Institut Lorrain du Coeur et des Vaisseaux, CHU Nancy, Vandoeuvre-les-Nancy, France
- Principal Investigator: Ulf Dahlstrom, Professor, Linkoping University Hospital, Sweden
- Principal Investigator: P Van der Meer, Doctor, University Medical Center Groningen, the Netherlands
- Principal Investigator: Franz Kleber, Professor, Klinikum Ernst von Bergmann, Akademisches Lehrankenhaus der Charite Universitätsmedizin Berlin, Germany
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- BSTE-0135
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Failure
-
Tufts Medical CenterMetro West Medical CenterCompletedCongestive Heart Failure | Diastolic Heart Failure | Systolic Heart FailureUnited States
-
Abbott Medical DevicesCompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure NYHA Class II | Heart Failure NYHA Class III | Heart Failure With Reduced Ejection Fraction | Heart Failure NYHA Class IV | Heart Failure With Normal Ejection Fraction | Heart Failure; With Decompensation | Heart Failure...United States, Canada
-
Manipal UniversityUnknownHeart Failure | Decompensated Heart Failure | Acute Heart Failure | Diastolic Heart Failure | Systolic Heart FailureIndia
-
University Hospital, MontpellierCompletedHeart Failure | Diastolic Heart Failure | Systolic Heart Failure Stage CFrance
-
VA Eastern Colorado Health Care SystemNational Institute on Aging (NIA)CompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection Fraction | Heart Failure; With Decompensation | Heart Failure,Congestive | Heart Failure AcuteUnited States
-
Lancaster General HospitalLouise von Hess Medical Research InstituteEnrolling by invitationDiastolic Heart FailureUnited States
-
Wake Forest UniversityCompletedHeart Failure, Congestive | Heart Failure With Preserved Ejection Fraction
-
Wake Forest UniversityNational Institute on Aging (NIA)CompletedHeart Failure, Congestive | Diastolic Heart FailureUnited States
-
Giresun UniversityIstanbul University - Cerrahpasa (IUC)RecruitingHeart Failure | Diastolic Heart Failure | Systolic Heart FailureTurkey
-
US Department of Veterans AffairsCompleted
Clinical Trials on Interventions with heart failure medications
-
Novartis PharmaceuticalsRecruiting
-
Xinjiang Medical UniversityFirst Affiliated Hospital of Xinjiang Medical UniversityRecruitingHeart Failure With Preserved Ejection Fraction | Renal DenervationChina
-
University College, LondonUniversity College London Hospitals; Barts & The London NHS Trust; British Heart...RecruitingHeart Failure | HER2-positive Breast Cancer | Cardiotoxicity | Cancer, Therapy-RelatedUnited Kingdom
-
LoneStar Heart, Inc.Not yet recruitingHeart Failure | Dilated Cardiomyopathy | Heart Failure With Reduced Ejection Fraction
-
LoneStar Heart, Inc.CompletedHeart Failure | Dilated CardiomyopathyItaly, Germany, Australia, Netherlands, New Zealand, Romania
-
Shanghai 10th People's HospitalFirst Affiliated Hospital, Sun Yat-Sen University; Tongji Hospital; Nanfang Hospital... and other collaboratorsUnknown
-
Central Hospital, Nancy, FranceUnknown
-
Paracor Medical, IncTerminatedHeart FailureUnited States, Canada
-
Maastricht University Medical CenterMaastricht UniversityCompleted
-
Cardiovascular and Pulmonary Rehabilitation Center...Institut National de la Santé Et de la Recherche Médicale, France; University... and other collaboratorsCompleted